Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Licenses Epigenetic PCR Technology to Oncgnostics

NEW YORK (GenomeWeb) – MDxHealth today announced it has licensed its methylation-specific PCR technology to molecular diagnostics firm Oncgnostics for use in a cervical cancer test.

The agreement grants Jena, Germany-based Oncgnostics a limited, non-transferable, non-exclusive, worldwide license for diagnostic applications in cervical cancer.

"This technology allows for the accurate and sensitive assessment of DNA methylation markers included in our first test, GynTect, which is intended for the early detection of cervical neoplasias that may progress to cancer," Oncgnostics CEO Alfred Hansel said in a statement.

In return, MDxHealth will receive upfront and milestone payments and royalties on net sales.

"DNA methylation is a proven diagnostic tool for cancer detection," said MDxHealth CEO Jan Groen, pointing to three existing products on the market based on the firm's proprietary technology and biomarkers: its own offerings ConfirmMDx for prostate cancer and PredictMDx for glioblastoma, as well as Exact Sciences' Cologuard test for colorectal cancer screening.

Financial details were not disclosed. 

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.